Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are  evaluating two distinct encapsulation therapies. Encapsulated cell  replacement therapy involves surrounding cells with the potential to secrete insulin with a protective barrier or device and implanting them in the body using a minor surgical procedure. The implanted encapsulated beta cells will sense a person’s glucose levels and produce insulin as needed, while the barrier shields them from the body’s immune system.

Click here to read the full article.